Post-hoc analysis from open-label Phase 3 study shows treatment with cenobamate led to a reduction of concomitant anti-seizure medications (ASMs) while maintaining ≥50% and 100% seizure reduction ...

"Road to Reduction" Begins Airing Today Raising Awareness of XCOPRI ® (cenobamate tablets) CV and the Journey to Seizure Management for People Living with Epilepsy PARAMUS, N.J., May 19, 2025 ...

SK Life Science will also host the "Prioritizing Seizure Treatments Through Real-World Patient Case Studies Symposium," an expert led panel to advance the discussion regarding the unmet need for ...

PARAMUS, N.J., April 9, 2024 /PRNewswire/ -- SK Life Science, Inc., a U.S. pharmaceutical company in pursuit of developing treatments that will change the future of central nervous system (CNS) ...

PARAMUS, N.J., April 4, 2025 /PRNewswire/ -- SK Life Science, Inc., a global leader in developing treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., ...

SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, ...